Literature DB >> 29485298

The Danish version of Lymphoedema Functioning, Disability and Health Questionnaire (Lymph-ICF) for breast cancer survivors: Translation and cultural adaptation followed by validity and reliability testing.

Karin R Grarup1, Nele Devoogdt2, Liv Inger Strand3.   

Abstract

PURPOSE: To translate and culturally adapt the Lymphoedema Functioning, Disability and Health Questionnaire (Lymph-ICF) for breast cancer survivors with arm lymphedema into Danish and examine its content validity and reliability.
METHODS: (1) Translation and cultural adaptation was performed in 10 steps following international guidelines (International Society for Pharmacoeconomics and Outcome Research); (2) cognitive interviewing (step 7) was conducted in 15 women with breast cancer related arm lymphedema to explore understandability, interpretation, and cultural relevance; (3) after adjustments, content validity (N = 52) was explored by interviews; and (4) reliability (N = 50) examined by intraclass correlation coefficients (ICC) statistics and Cronbach alpha analysis.
RESULTS: Cognitive interviewing lead to an adapted and improved version of the translated questionnaire. Content validity was supported. Internal consistency (α) for all questions was .98 and ranged for the different domains between 0.92 and 0.97. Test-retest reliability for the total score was highly satisfactory, ICC = 0.95, standard error of measurement (SEM) = 4.5 and smallest detectable change = 12.5. ICC values for the domains ranged from 0.84 to 0.94. SEM values differed for the domains, 6.4 (physical function), 5.7 (mobility activities), 7.09 (life and social activities), 9.1 (mental functions), and 10.2 (household activities).
CONCLUSION: The translated and adjusted Lymph-ICF DK (Denmark) is reliable and valid, allowing for assessing self-reported impairments in function, activity limitations, and participation restrictions in Danish patients with breast cancer-related arm lymphedema.

Entities:  

Keywords:  Danish version; Lymphedema; Lymphoedema Functioning, Disability and Health Questionnaire; breast cancer; cognitive interviewing; translation

Mesh:

Year:  2018        PMID: 29485298     DOI: 10.1080/09593985.2018.1443186

Source DB:  PubMed          Journal:  Physiother Theory Pract        ISSN: 0959-3985            Impact factor:   2.279


  5 in total

1.  Validation of a newly developed questionnaire regarding clinical history in patients with breast and colorectal cancers.

Authors:  Zamaneh Vafaei; Jamshid Najafian; Masood Shekarchizadeh; Samaneh Mostafavi; Ali Darakhshandeh; Mohammadreza Khosravifarsani; Farzaneh Ashrafi; Mehran Sharifi; Noushin Mohammadifard; Mohammad Hassan Emami; Shaghayegh Haghjooy-Javanmard; Nizal Sarrafzadegan
Journal:  ARYA Atheroscler       Date:  2021-11

2.  Effectiveness of an expert assessment and individualised treatment compared with a minimal home-based exercise program in women with late-term shoulder impairments after primary breast cancer surgery: study protocol for a randomised controlled trial.

Authors:  Kim Michéle Feder; Hans Bjarke Rahr; Marianne Djernes Lautrup; Heidi Klakk Egebæk; Robin Christensen; Kim Gordon Ingwersen
Journal:  Trials       Date:  2022-08-20       Impact factor: 2.728

Review 3.  Patient-Reported Outcome Measures in Lymphedema: A Systematic Review and COSMIN Analysis.

Authors:  Louise Marie Beelen; Anne-Margreet van Dishoeck; Elena Tsangaris; Michelle Coriddi; Joseph H Dayan; Andrea L Pusic; Anne Klassen; Dalibor Vasilic
Journal:  Ann Surg Oncol       Date:  2020-11-28       Impact factor: 5.344

4.  The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment.

Authors:  Mads G Jørgensen; Navid M Toyserkani; Frederik G Hansen; Anette Bygum; Jens A Sørensen
Journal:  NPJ Breast Cancer       Date:  2021-06-01

Review 5.  Psychometric Properties of Quality of Life Questionnaires for Patients with Breast Cancer-Related Lymphedema: A Systematic Review.

Authors:  Estu Meilani; Asfarina Zanudin; Nor Azlin Mohd Nordin
Journal:  Int J Environ Res Public Health       Date:  2022-02-22       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.